Arvinas Inc (ARVN) COM USD0.001

Sell:$8.50Buy:$9.85$0.25 (2.78%)

NASDAQ:0.52%
Market closed | Prices delayed by at least 15 minutes
Sell:$8.50
Buy:$9.85
Change:$0.25 (2.78%)
Market closed | Prices delayed by at least 15 minutes
Sell:$8.50
Buy:$9.85
Change:$0.25 (2.78%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Key people

John G. Houston
Chairman of the Board, President, Chief Executive Officer
Andrew Saik
Chief Financial Officer, Treasurer
Ian Taylor
President - Research and Development
Angela Cacace
Chief Scientific Officer
Jared Morris Freedberg
General Counsel
Noah Berkowitz
Chief Medical Officer
Randy Teel
Chief Business Officer
Briggs W. Morrison
Lead Independent Director
Sunil Agarwal
Independent Director
Linda C. Bain
Independent Director
Everett V. Cunningham
Independent Director
Edward Kennedy
Independent Director
Click to see more

Key facts

  • EPIC
    ARVN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US04335A1051
  • Market cap
    $598.32m
  • Employees
    430
  • Shares in issue
    68.77m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.